Gland Pharma Grants 1,626 Employee Stock Options Under ESOP 2025 Scheme
Gland Pharma Limited's ESOP Compensation Committee approved the grant of 1,626 employee stock options to one employee under ESOP 2025 scheme on March 03, 2026. The options are structured with two pricing tiers: 1,073 options at ₹897.40 and 553 options at ₹1.00. The three-year vesting schedule begins March 03, 2027, with employees having two years post-vesting to exercise options. This inaugural grant under the newly established scheme complies with SEBI regulations and demonstrates the company's commitment to employee incentivization.
*this image is generated using AI for illustrative purposes only.
Gland Pharma Limited has announced the grant of 1,626 employee stock options to one employee under its Employee Stock Option Scheme 2025. The ESOP Compensation Committee of the Board of Directors approved this grant on March 03, 2026, marking the first grant under the newly established scheme.
Grant Details and Pricing Structure
The stock option grant comprises two distinct pricing tiers designed to provide different incentive structures:
| Option Category: | Number of Options | Exercise Price |
|---|---|---|
| Market-linked Options: | 1,073 | ₹897.40 |
| Face Value Options: | 553 | ₹1.00 |
| Total Options: | 1,626 | Mixed Pricing |
The exercise price of ₹897.40 represents 50% of the closing price of the equity share on NSE as of March 03, 2026. Since the grant date fell on a trading holiday, the closing price of the preceding day, March 02, 2026, was considered for calculation.
Vesting Schedule and Exercise Timeline
The options follow a structured three-year vesting schedule designed to promote employee retention:
| Vesting Period: | Percentage | Vesting Date |
|---|---|---|
| First Year: | 34% | March 03, 2027 |
| Second Year: | 33% | March 03, 2028 |
| Third Year: | 33% | March 03, 2029 |
Once vested, employees have a maximum period of two years from the respective vesting dates to exercise their options. This provides flexibility while ensuring timely conversion of options to equity shares.
Regulatory Compliance and Scheme Framework
The grant operates under full compliance with SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021. The ESOP 2025 scheme was established following previous intimations dated May 22, 2025, and July 03, 2025, indicating the company's systematic approach to employee incentivization.
The stock options will be administered by the ESOP Compensation Committee of the Board of Directors, ensuring proper governance and oversight of the scheme implementation.
Current Status and Future Implications
As this represents the inaugural grant under ESOP 2025, several operational metrics remain in preliminary stages:
- No options have been exercised to date
- No money has been realized from option exercises
- No options have lapsed
- No variations in terms have been implemented
The company has filed the necessary disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, maintaining transparency with stakeholders regarding this employee benefit initiative.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.50% | -1.48% | +7.09% | -6.88% | +10.94% | -23.91% |
15
